Key result
RNF213 p.Arg4810Lys variant linked to poorer BPA response and ~600% higher complication odds vs noncarriers.
Why the study?
The RNF213 p.Arg4810Lys variant has been identified in CTEPH, but its influence on the response to balloon pulmonary angioplasty remained unclear.
Does the heterozygous RNF213 p.Arg4810Lys variant worsen clinical response and increase complications following balloon pulmonary angioplasty in patients with chronic thromboembolic pulmonary hypertension?
Cohort (n=93)
Does the heterozygous RNF213 p.Arg4810Lys variant worsen clinical response and increase complications following balloon pulmonary angioplasty in patients with chronic thromboembolic pulmonary hypertension?
The RNF213 p.Arg4810Lys variant in CTEPH patients is associated with a poorer hemodynamic and functional response to balloon pulmonary angioplasty and a significantly increased risk of procedural complications.
Answers are grounded in this paper and cite their sources.
May warrant caution with BPA in RNF213 variant carriers; hypothesis-generating for genotype-guided strategies pending validation.
Background The heterozygous ring finger protein 213 (RNF213) p.Arg4810Lys variant has been identified in patients with chronic thromboembolic pulmonary hypertension (CTEPH). This study aimed to clarify the influence of the RNF213 p.Arg4810Lys variant on the response to balloon pulmonary angioplasty (BPA) in patients with CTEPH. Methods We retrospectively analyzed 93 patients with CTEPH who underwent BPA by analyzing the RNF213 p.Arg4810Lys variant. Clinical parameters and hemodynamics following BPA were compared between RNF213 p.Arg4810Lys variant carriers and noncarriers, along with BPA‐related complications. Results Among 93 patients, 7 (8%) were heterozygous RNF213 p.Arg4810Lys variant carriers and 86 (92%) were noncarriers. Both groups showed significant improvements in mean pulmonary artery pressure and pulmonary vascular resistance following BPA. However, the 6‐minute walk distance, symptoms, cardiac index, and right ventricular function did not significantly improve in heterozygous RNF213 variant carriers, whereas noncarriers showed notable improvements. Group differences in mean change from baseline to follow‐up were significant in cardiac index (0.4 L/min per m 2 [95% CI, 0.1–0.8]; P =0.019), 6‐minute walk distance (70 m [95% CI, 6–135]; P =0.036), and right ventricular ejection fraction (9% [95% CI, 5–12]; P <0.001), all favoring noncarriers. Of the 515 BPA procedures, complications were significantly higher in variant carriers than in noncarriers (25% versus 8%; P <0.001). Multivariate logistic regression analysis indicated a significant association between the RNF213 p.Arg4810Lys variant and BPA complications (adjusted odds ratio, 7.0 [95% CI, 1.1–44.4]; P =0.038). Conclusions Heterozygous RNF213 p.Arg4810Lys variant carriers exhibited a poor response to BPA, suggesting that the RNF213 p.Arg4810Lys variant could be a risk factor for BPA complications.
No takes yet. Share an insight, caveat, or question.
Kiko et al. (2025) conducted a cohort in Chronic thromboembolic pulmonary hypertension (n=93). Heterozygous RNF213 p.Arg4810Lys variant vs. Noncarriers was evaluated on BPA-related complications (OR 7.0, 95% CI 1.1-44.4, p=0.038). Heterozygous RNF213 p.Arg4810Lys variant carriers exhibited poorer responses to BPA and higher complication rates than noncarriers.
Synapse has enriched 10 related papers. Consider them for comparative context: